Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT05815186 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT05815186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05815186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2024
Completion date
April 30, 2026
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer with kras g12c mutation